Boundless Bio, Inc. (BOLD)
(Real Time Quote from BATS)
$4.11 USD
-0.04 (-0.96%)
Updated Jul 8, 2024 01:30 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BOLD 4.11 -0.04(-0.96%)
Will BOLD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BOLD based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BOLD
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Boundless Bio Inc.: A Strong Buy on Robust Pipeline Progress and Financial Stability
Boundless Bio GAAP EPS of -$12.27 misses by $11.54
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
Boundless Bio Inc. Shifts Corporate Updates to IR Website